Lumipulse® G FT4-N (Free Thyroxine)
Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of free thyroxine (FT4) in serum or plasma.
The assay utilises proven CLEIA (ChemiLuminescent Enzyme Immunoassay) technology with results that are available in up to 35 minutes.
Product number 294680
Product number 230503
-
Details
CLEIA - ChemiLuminescent Enzyme Immunoassay
Test principle: One-step competitive assay
Clinical background
FT4 (Free Thyroxine)
Free thyroxine possesses only weak thyroid hormone activity while free triiodothyronine (FT3) has active thyroid hormone action.
It is considered that FT4 acts only as a precursor to FT3.
However, since FT4 is converted to T3 in tissue, which gives rise to such effects as promoting metabolism, the FT4 concentration in blood is considered to be a valuable marker providing a direct indication of thyroid function status.
While the blood T4 concentration changes with quantitative and qualitative variations in TBP (thyroxine-binding protein), blood FT4 is not influenced by TBP alteration and therefore more closely reflects the in vivo metabolic status.
The FT4 assay is useful in the diagnosis and monitoring therapeutic effect of various thyroid diseases.
See the LUMIPULSE G1200 working in this video:
-
Documentation
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all regulatory documentation right away.
Get access to this section and more
Create a free eServices account now and instantly access multiple digital resources:
- Regulatory product documentation
- Selected scientific posters
- Product leaflets
- How-to videos and more…
-
FAQ
How does the coronavirus disease Covid-19 impact Fujirebio's operations?
Please see the following statement on the impact of coronavirus disease Covid-19 on the operations of Fujirebio Europe (updated January 19, 2021).
-
Related products
-
Product inquiry
